The present invention is directed to novel crystalline forms of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamidehydrochloride, to the use of said crystalline forms in treating diseases andconditions mediated by modulation of voltage-gated sodiumchannels, to compositions containing said crystalline forms and processes fortheir preparation.